CHUV
Les activités du CHUV
MENU
Centre du sein
Accueil > Recherche > Publications > Publications 2011

Publications 2011


  1. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators.
    TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
    Lancet Oncol. 2011 Jun;12(6):527-39. doi: 10.1016/S1470-2045(11)70094-8. Epub 2011 May 11. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47. PubMed PMID: 21570352.

  2. Cottier O, Fiche M, Meuwly JY, Delaloye JF.
    Dermatofibrosarcoma presenting as a nodule in the breast of a 75-year-old woman: a case report.
    J Med Case Rep. 2011 Oct 5;5:503. doi: 10.1186/1752-1947-5-503. PubMed PMID: 21975420; PubMed Central PMCID: PMC3197540.

  3. DeCensi A, Sun Z, Thürlimann B, McIntosh C, Guerrieri-Gonzaga A, Monnier A, Tondini C, Campone M, Mauriac L, Zaman K, Schönenberger A, N. Price K, D. Gelber R, Goldhirsch A, S. Coates A, Aebi S for the BIG 1-98 Collaborative and International Breast Cancer Study Groups.
    Bone mineral density in participants of trial BIG 1-98 comparing adjuvant letrozole versus tamoxifen or their sequence.
    ASCO Annual Meeting June 2011; Poster discussion (Abstract 516).

  4. Dey-Guha I, Wolfer A, Yeh A.C, Albeck J. G, Darp R, Leon E, Wulfkuhle J, Petricoin E.F, Wittner B. S. Ramaswamy S. 2011.
    Asymmetric cancer cell division regulated by AKT.
    Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12845-50. doi: 10.1073/pnas.1109632108. Epub 2011 Jul 14. PubMed PMID:21757645.

  5. Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.
    Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
    Ann Oncol. 2011 Oct;22(10):2216-26. doi: 10.1093/annonc/mdq735. Epub 2011 Feb 16. PubMed PMID: 21325445.

  6. Kerschgens J, Renaud S, Schütz F, Grasso L, Egener-Kuhn T, Delaloye JF, Lehr HA, Vogel H, Mermod N.
    Protein-binding microarray analysis of tumor suppressor AP2α target gene specificity.
    PLoS One. 2011;6(8):e22895. doi: 10.1371/journal.pone.0022895. Epub 2011 Aug 18. PubMed PMID: 21876733; PubMed Central PMCID: PMC3158074.

  7. Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B.
    Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
    Endocr Relat Cancer. 2011 Mar 9;18(2):257-64. doi: 10.1530/ERC-10-0317. Print 2011 Apr. PubMed PMID:21317203.

  8. Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C.
    Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.
    Cancer Res. 2011 Jun 1;71(11):3781-91. doi: 10.1158/0008-5472.CAN-10-3684. Epub 2011 Apr 20. PubMed PMID: 21507936.

  9. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J.
    Interactions between cancer stem cells and their niche govern metastatic colonization.
    Nature. 2011 Dec 7;481(7379):85-9. doi: 10.1038/nature10694. PubMed PMID: 22158103.

  10. Nobile A, Treboux A, Delaloye JF, Zaman K, Jeanneret-Sozzi W, Schaefer SC, Lehr HA.
    What makes a good pathology report ?
    Eur J Cancer. 2011 Sep;47(14):2082-3. doi: 10.1016/j.ejca.2011.06.033. Epub 2011 Jul 19. PubMed PMID: 21764296.

  11. Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K.
    Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
    Ann Oncol. 2011 Jan;22(1):80-5. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1. PubMed PMID:20595448.

  12. Tsoutsou PG, Sozzi WJ, Matzinger O, Ozsahin M.
    Personalizing locoregional treatment in the adjuvant setting of early breast cancer on the basis of molecular background: an exciting enigma.
    J Clin Oncol. 2011 Dec 10;29(35):4721-2; author reply 4723-4. doi: 10.1200/JCO.2011.38.5922. Epub 2011 Oct 31. PubMed PMID: 22042936.

  13. Voutsadakis IA, Zaman K, Leyvraz S.
    Breast sarcomas: current and future perspectives.
    Breast. 2011 Jun;20(3):199-204. doi: 10.1016/j.breast.2011.02.016. Epub 2011 Mar 12. Review. PubMed PMID: 21398126.

  14. Zaman K, Bellavia M, Ambrosetti A, Primi MP, Ifticene Treboux A, Kohlik M, Brioschi PA, de Candolle G, de Ziegler D, Petignat P, Delaloye JF, Wunder D, Perey L.
    Results of the Western Swiss Fertility Preservation Network for young women with breast cancer: Réseau Romand de Cancer et Fertilité (RRCF).
    ASCO Annual Meeting 2011 (abstract e19599).

  15. Zaman K, Durando X, Baurain JF, Humblet Y, Mazzeo F, Bostnavaron M, Meheust N, Monnoyer-Favrel S, Machiels JP, Bauer J.
    A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.
    Breast Cancer Res Treat. 2011 Jun;127(3):689-96. doi: 10.1007/s10549-011-1446-x. Epub 2011 Mar 26. PubMed PMID: 21442199.

  16. Zaman K, Rochlitz C, Ruhstaller T, Thurlimann B, Aebi S, von Moos R, Mamot C, Gabriel N, Crowe S, Ruegg C.
    Plasma level of MMP-9 as predictive factor for response and progression free survival in patients treated with bevacizumab (Bev) and pegylated liposomal doxorubicin (PLD): SAKK 24/06.
    IMPAKT Congress 5-7 May 2011, Brussels. Abstract number 118P.